Drugs / AN-1792
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Clinical hold | US (FDA) | — | Alzheimer disease | — | “Unfortunately, the AN-1792 vaccine was suspended by the FDA due to adverse effects.” alzamend.com ↗ “Unfortunately, the AN-1792 vaccine was suspended by FDA due to adverse effects.” alzamend.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00021723 | Sep 2001 → Sep 2003 | Alzheimer disease | JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AN-1792 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00021723 ↗ |
| Known as | AIP-001 | “AN-1792 also known as AIP-001” NCT00021723 ↗ |
| Route | Intramuscular | “intramuscular AN-1792” NCT00021723 ↗ |